SCHEMBL6444252

SCHEMBL6444252

Cn1nnc(-c2ccc(F)c3c(C(=O)C(=O)N4CCN(C(=O)c5ccc(Cl)o5)CC4)c[nH]c23)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.36
CYP2C9 P11712 2/20 0.36
RAB9A P51151 1/20 0.35
CYP3A4 P08684 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2B6 P20813 1/20 0.34
CYP2C19 P33261 1/20 0.34
KCNH2 Q12809 1/20 0.34
CHRNB2 P17787 2/20 0.32
CHRNB4 P30926 2/20 0.32
CHRNA3 P32297 2/20 0.32
CHRNA4 P43681 2/20 0.32
CHRNA7 P36544 1/20 0.32
HTR3A P46098 1/20 0.32
KMT2A Q03164 3/20 0.32
MAPT P10636 2/20 0.31
BDKRB1 P46663 1/20 0.31
HCRTR1 O43613 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445809 0.92 TSHR (0.39) PARP1CYP2C9RAB9ACYP3A4CYP1A2
SCHEMBL6442414 0.86 RAB9A (0.51) CYP2C9RAB9AKMT2AMAPTMEN1
SCHEMBL6446655 0.85 PARP1 (0.36) PARP1CYP2C9RAB9ACYP3A4CYP1A2
SCHEMBL6441276 0.85 CYP2C9 (0.51) CYP2C9RAB9ACYP3A4CYP1A2CYP2C8
SCHEMBL6441663 0.81 GAA (0.39) CYP2C9RAB9ACYP3A4CYP1A2CYP2C8
SCHEMBL6442692 0.77 TSHR (0.40) PARP1CYP2C9RAB9ACYP3A4CYP1A2
SCHEMBL6442058 0.75 CYP2C9 (0.46) CYP2C9RAB9ACYP3A4CYP1A2CYP2C8
SCHEMBL6445395 0.75 CYP2C9 (0.47) CYP2C9RAB9ACYP3A4CYP1A2CYP2C8
SCHEMBL6441584 0.75 CYP2C19 (0.56) PARP1CYP2C9CYP3A4CYP1A2CYP2C8
SCHEMBL6440957 0.75 CYP2C9 (0.44) PARP1CYP2C9RAB9ACYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002004440-A9 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-11-03 WO claimed
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA PARP1 734/4885CYP2C9 2370/4885RAB9A 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.